CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.
Publication
, Conference
Kilburn, L; Landi, D; Leary, S; Ziegler, D; Baxter, P; Franson, A; McCowage, G; Waanders, A; Van Der Lugt, J; Oren, M; Gerber, N; Gottardo, N ...
Published in: Neuro-Oncology
November 14, 2022
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Neuro-Oncology
DOI
ISSN
1522-8517
Publication Date
November 14, 2022
Volume
24
Issue
7
Start / End Page
vii89 / vii89
Location
Tampa Convention Center, Tampa Bay, FL
Publisher
Oxford University Press
Conference Name
2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Kilburn, L., Landi, D., Leary, S., Ziegler, D., Baxter, P., Franson, A., … Hansford, J. (2022). CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In Neuro-Oncology (Vol. 24, pp. vii89–vii89). Tampa Convention Center, Tampa Bay, FL: Oxford University Press. https://doi.org/10.1093/neuonc/noac209.333
Kilburn, Lindsay, Daniel Landi, Sarah Leary, David Ziegler, Patricia Baxter, Andrea Franson, Geoffrey McCowage, et al. “CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.” In Neuro-Oncology, 24:vii89–vii89. Oxford University Press, 2022. https://doi.org/10.1093/neuonc/noac209.333.
Kilburn L, Landi D, Leary S, Ziegler D, Baxter P, Franson A, et al. CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. In: Neuro-Oncology. Oxford University Press; 2022. p. vii89–vii89.
Kilburn, Lindsay, et al. “CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors.” Neuro-Oncology, vol. 24, no. 7, Oxford University Press, 2022, pp. vii89–vii89. Manual, doi:10.1093/neuonc/noac209.333.
Kilburn L, Landi D, Leary S, Ziegler D, Baxter P, Franson A, McCowage G, Waanders A, Van Der Lugt J, Oren M, Gerber N, Gottardo N, Khuong-Quang D-A, Nysom K, Bailey S, Driever P, Perreault S, Witt O, Hahn S, Hargrave D, Hassall T, Nada J, Jin Kang H, Larouche V, Toledano H, Cassie K, Abdelbaki M, Chi S, Gardner S, Whipple N, Mueller S, Blackman S, Zhao X, Da Costa D, Cox M, Packer R, Hansford J. CTNI-68. FIREFLY-1 (PNOC026): Phase 2 study of pan-RAF inhibitor tovorafenib in pediatric and young adult patients with RAF-altered recurrent or progressive low-grade glioma or advanced solid tumors. Neuro-Oncology. Oxford University Press; 2022. p. vii89–vii89.
Published In
Neuro-Oncology
DOI
ISSN
1522-8517
Publication Date
November 14, 2022
Volume
24
Issue
7
Start / End Page
vii89 / vii89
Location
Tampa Convention Center, Tampa Bay, FL
Publisher
Oxford University Press
Conference Name
2022 Society for Neuro-Oncology’s 27th Annual Scientific Meeting and Education Day
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1109 Neurosciences